According to FutureWise analysis, the market for Acute Hepatic Porphyria Treatment is expected to be US$ 0.01 billion in 2031 at a CAGR of 5.2% over the forecast period of 2025-2033.
Acute Hepatic Porphyria (AHP) is a group of rare genetic disorders characterized by the deficiency of specific enzymes involved in synthesizing heme, a crucial component of hemoglobin. The absence of these enzymes leads to the accumulation of certain intermediate compounds called porphyrins in the body, causing various symptoms. The objective of the treatment is to relieve the symptoms associated with acute attacks. Medications such as opioids or non-opioid analgesics can be administered to manage severe abdominal pain. For instance, Givosiran (Kineta®) is a first-of-its-kind RNAi therapy that has been shown to prevent acute attacks in patients with acute intermittent porphyria (AIP). It was approved by the EMA in 2022 and is currently under review by the US FDA.
Anti-nausea drugs may be prescribed to alleviate vomiting, and anti-anxiety medications can help control associated anxiety and agitation. Certain medications, hormones, and lifestyle factors can trigger acute attacks in individuals with AHP. It is essential to identify and avoid these triggers. Common triggers include certain medications (such as barbiturates, sulfonamide antibiotics, and hormonal medications), alcohol, fasting, hormonal changes (such as those occurring during menstruation or pregnancy), and stress. As AHP is a genetic disorder, individuals diagnosed with the condition may benefit from genetic counselling. Understanding the inheritance pattern can assist in evaluating the likelihood of passing on the disease to offspring and making informed decisions regarding family planning.
FutureWise Market Research has published a report that provides an insightful analysis of Acute Hepatic Porphyria Treatment Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes the stature of key manufacturers operational in this industry.
According to the analysis conducted by FutureWise research analysts, Acute Hepatic Porphyria Treatment Market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition to providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organization to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.